AvidBiotics granted rights to UCLA's diversity generator platform technology.AvidBiotics Corporation (San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden , CA) announced the receipt of an exclusive, worldwide license to the patent rights associated with UCLA's Diversity Generator technology discovered by Jeffery F. Miller, PhD. and colleagues at UCLA UCLA University of California at Los Angeles UCLA University Center for Learning Assistance (Illinois State University) UCLA University of Carrollton, TX and Lower Addison, TX . The technology, based upon natural processes that bacteria and bacteriophages use to generate enormous diversity for survival, has broad potential uses in human therapeutics and diagnostics, veterinary medicine veterinary medicine, diagnosis and treatment of diseases of animals. An early interest in animal diseases is found in ancient Greek writings on medicine. Veterinary medicine began to achieve the stature of a science with the organization of the first school in the and agriculture, and research tools and reagents. Professor Jeffery Miller commented, "The discovery and then deployment of natural processes for the improvement of health is one of a scientist's greatest rewards. My colleagues and I are delighted that AvidBiotics is deploying our discovered technology to address the threat of infections by antibiotic-resistant bacteria. We look forward to following their progress and development of other applications in the field of protein engineering." The diversity generating system (DGR DGR Deductible Gift Recipient (Australian tax exemption) DGR Dangerous Goods Regulations DGR Delibera Giunta Regionale (Italy) DGR Directorate General Resettlement (India) ) has evolved naturally in certain bacteriophages, bacteria, and spirochetes, and deploys a novel, extremely focused mutagenic mutagenic inducing genetic mutation. process to generate diversity in receptor-ligand ("lock-and-key") interactions without putting at risk the structural integrity of the supporting scaffold of the key. This powerful diversity generator is second only to that of the immunity system for the magnitude of diversity that can be created. In addition, the DGR system as compared to antibody diversity system is far less complex structurally and easier to manipulate. "This elegant process of generating diversity in nature has many potential applications in the life sciences. We are excited by the opportunity to build on Nature's successes," stated David Martin David Martin may refer to: Politicians
AvidBiotics is a biotherapeutics company with a proprietary technology platform focused on the development of genetically engineered genetically engineered adjective Recombinant, see there protein products for the treatment of major bacterial diseases, with particular emphasis on antibiotic-resistant bacteria. Founded in 2004, by David Martin, Jr. MD, Jeffery F. Miller, PhD., and James Knighton, on technology discovered by Dr. Miller and colleagues, AvidBiotics has technology that enables customization of protein structures in a precise manner. The core technology has direct applicability to human therapeutics and diagnostics, veterinary medicine and agriculture, and research tools and reagents. AvidBiotics Corporation +1-650-799-5415 www.avidbiotics.com |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion